The record
Written from the 1 report below. Nothing here is unsourced.
- US President Donald Trump has proposed a phased tariff framework on imported generic medicines, keeping tariffs at zero until August 1, 2028, then 100 per cent for a year and 200 per cent from August 1, 2029.
- Indian pharmaceutical experts say the move should push the industry to diversify beyond the US market and invest in innovation.
- They caution that higher medicine costs could hurt patient adherence to long-term treatments and that relocating manufacturing to the US would take years due to regulatory, technology and investment hurdles.
- The report highlights that the proposal aims to encourage drug manufacturing in the US but has sparked debate over its long-term impact on affordable medicine access.
What to watch next
- Clarification of the finer details of the proposed US tariff framework, which experts say remain unclear
- Whether Indian pharma companies begin diversifying export markets and strengthening domestic innovation
- Any changes to the phased tariff timeline or rates as the 2028 start date approaches
Coverage1
1 report
English national1
All filed from India
Named United States · India · Agra · ENTOD Pharmaceuticals · Sarojini Naidu Medical College · Donald Trump · Nikhil K Masurkar · Organisation of Pharmaceutical Producers of India · Paddy Advisory Services LLP · Shefali Mazumdar · Vivek Padgaonkar
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.